Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer

European Journal of Cancer

Volumn 38, Issue SUPPL. 6, 2002, Pages

  Piccart, M J ^a   Cardoso, F ^a   Atalay, G ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ALOPECIA; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEADACHE; HORMONAL THERAPY; HUMAN; MYALGIA; NAUSEA; PERIPHERAL EDEMA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; VAGINA BLEEDING; WEIGHT GAIN;

EID: 0036754206     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(02)00285-x     Document Type: Article

References (6)

1. Hamilton A., Piccart M.J. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol. 10:1999;377-384.
2. Mouridsen H., Gershanovich M., Sun Y.et al. Superior efficacy of Letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. results of a phase IU study of the international letrozole breast cancer group J Clin Oncol. 19:2001;2596-2606.
3. Dombernowsky P., Smith I., Falkson G.et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer. double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate J Clin Oncol. 16:1998;453-461.
4. Buzdar A.V., Douma J., Davidson N.et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 19:2001;3357-3366.
5. Nabholtz J.M., Bonneterre J., Buzdar A.U.et al. Preliminary results of two multi-center trials comparing the efficacy and tolerability of Arimidex' (anastrozole) and tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). J Clin Oncol. 19:2001;3357-3366.
6. Dirix L., Piccart M., Lohrisch C.et al. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in first line hormone therapy (HT) of postmenopausal patients (pts) with metastatic breast cancer (MBC). a European organization for the research and treatment of cancer (EORTC) randomized phase II trial (10951) Proc. ASCO. 20:2001;29a. a(abstr 114).